Stock Analiz

CRISPR Therapeutics AG (CRSP) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

CRISPR Therapeutics’s revenue went from $5M in fiscal 2016 to $4M in fiscal 2025, a decline of about 4.2% a year.

Net income in fiscal 2025 was -$582M, a net margin of -16569.8%; the best year in this period was 2021 with $378M.

Over the twelve months to September 30, 2026, revenue was $25M and net income -$456M.

Free cash flow was -$346M in fiscal 2025 and positive in 2 of the 10 years shown.

The diluted share count rose 634% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $5M162017: $41M172018: $3M182019: $290M192020: $719000202021: $915M212022: $1M222023: $371M232024: $37M242025: $4M25$4M
Net income
2016: -$23M162017: -$68M172018: -$165M182019: $67M192020: -$349M202021: $378M212022: -$650M222023: -$154M232024: -$366M242025: -$582M25-$582M
Free cash flow
2016: -$56M162017: -$78M172018: -$99M182019: $50M192020: -$257M202021: $457M212022: -$533M222023: -$270M232024: -$145M242025: -$346M25-$346M
EPS (diluted)
2016: $-1.89162017: $-1.71172018: $-3.44182019: $1.17192020: $-5.29202021: $4.70212022: $-8.36222023: $-1.94232024: $-4.34242025: $-6.4725$-6.47

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$25M$4M$37M$371M$1M$915M$719000$290M$3M$41M$5M
Gross profit———————————
Operating income-$532M-$665M-$467M-$223M-$673M$374M-$354M$47M-$159M-$65M-$68M
Net income-$456M-$582M-$366M-$154M-$650M$378M-$349M$67M-$165M-$68M-$23M
EPS (diluted)$-4.72$-6.47$-4.34$-1.94$-8.36$4.70$-5.29$1.17$-3.44$-1.71$-1.89
R&D$291M$285M$310M$387M$462M$341M$221M$179M$114M$70M$42M
Revenue growth—−90.6%−90.0%+30885.5%−99.9%+127200.0%−99.8%+9169.9%−92.4%+693.9%+1990.7%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$375M-$345M-$143M-$260M-$496M$539M-$238M$57M-$96M-$70M-$53M
Capital spending-$2M-$914000-$2M-$9M-$37M-$82M-$18M-$7M-$3M-$8M-$3M
Free cash flow-$377M-$346M-$145M-$270M-$533M$457M-$257M$50M-$99M-$78M-$56M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks————————$57000——
Stock-based pay$70M$72M$87M$81M$98M$102M$66M$44M$35M$19M$11M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$2.0B$1.9B$1.7B$1.8B$2.4B$1.7B$944M$457M$240M$316M
Debt—$207M$224M$239M$244M$225M$61M$53M$0$0$0
Equity—$1.9B$1.9B$1.9B$1.9B$2.4B$1.7B$939M$392M$188M$233M
Total assets—$2.3B$2.2B$2.2B$2.2B$2.8B$1.8B$1.1B$489M$271M$345M
Shares (diluted)97M90M84M79M78M80M66M57M48M40M12M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin———————————
Operating margin-2114.8%-18933.7%-1250.4%-60.0%-56190.4%40.8%-49295.5%16.1%-5087.8%-157.7%-1319.3%
Net margin-1812.1%-16569.8%-981.5%-41.4%-54271.7%41.3%-48520.9%23.1%-5281.1%-166.7%-448.8%
FCF margin-1496.6%-9855.5%-387.7%-72.7%-44484.9%50.0%-35705.7%17.3%-3169.4%-190.0%-1082.0%
ROIC—-24.7%-17.1%-8.3%-31.7%14.2%-16.2%4.7%-32.0%-27.2%-23.1%
ROE—-30.3%-19.0%-8.2%-34.7%15.7%-21.0%7.1%-42.1%-36.4%-10.0%

Frequently asked questions

What is CRISPR Therapeutics’s annual revenue?

$4M in fiscal 2025 and $25M over the twelve months to September 30, 2026.

How much profit does CRISPR Therapeutics make?

Net income was -$582M in fiscal 2025 (net margin -16569.8%).

Is CRISPR Therapeutics’s revenue growing?

No: revenue fell 90.6% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.